DRACP, an open comprehensive data repository for anticancer peptides

With the discovery of the therapeutic activity of peptides, peptides have emerged as a promising class of anti-cancer agents due to their specific targeting, low toxicity, and potential for high selectivity. In particular, as peptide-drug conjugates enter the clinical stage, the coupling of targeted peptides with traditional chemotherapy drugs or cytotoxic agents will become a new direction in cancer treatment. To facilitate the development of anti-cancer peptide drugs, we have constructed DRACP, a novel, open, and comprehensive data repository for anticancer peptides (ACPs). The database is divided into peptide library and drug library. ACPs data were collected manually from published research articles, patents, and other protein or peptide databases. Data on drug library include clinically investigated and/or approved ACP drugs, which mainly come from the portal websites of drug regulatory authorities and organisations in different countries and regions. As of 10 June 2023, DRACP has a total of 6921 entries. We believe that DRACP will contribute to the design and screening of future ACP drugs.